Quoin Pharmaceuticals receives FDA approval for teenage Netherton Syndrome trials of drug QRX003.
Quoin Pharmaceuticals' shares soared after receiving FDA clearance to recruit teenage subjects aged 14 and older for its two ongoing clinical trials of QRX003, a potential treatment for Netherton Syndrome. This is the first time non-adult Netherton subjects will be tested in clinical studies conducted under an open-IND, which is expected to lead to a more robust data set for regulatory approval.
March 04, 2024
10 Articles